Ameritas Investment Partners’s Tvardi Therapeutics TVRD Stock Holding History

Ameritas Investment Partners’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.11K	Hold	349	–	–	﹤0.01%	3086
2025 Q4	$1.5K	Hold	349	–	–	﹤0.01%	3103
2025 Q3	$13.6K	Hold	349	–	–	﹤0.01%	2850
2025 Q2	$8.14K	Buy	+349	New	+$8.25K	﹤0.01%	3033
2024 Q2	–	Sell	-92	Closed	-$3.01K	–	3252
2024 Q1	$3.01K	Hold	92	–	–	﹤0.01%	3000
2023 Q4	$2.46K	Hold	92	–	–	﹤0.01%	3052
2023 Q3	$5.56K	Hold	92	–	–	﹤0.01%	2971
2023 Q2	$9.37K	Hold	92	–	–	﹤0.01%	2925
2023 Q1	$16.3K	Hold	92	–	–	﹤0.01%	2536
2022 Q4	$39.1K	Hold	92	–	–	﹤0.01%	2229
2022 Q3	$30K	Hold	92	–	–	﹤0.01%	2309
2022 Q2	$30K	Hold	92	–	–	﹤0.01%	2325
2022 Q1	$40K	Hold	92	–	–	﹤0.01%	2196
2021 Q4	$40K	Hold	92	–	–	﹤0.01%	2284
2021 Q3	$51K	Hold	92	–	–	﹤0.01%	2151
2021 Q2	$47K	Hold	92	–	–	﹤0.01%	2232
2021 Q1	$72K	Hold	92	–	–	﹤0.01%	1863
2020 Q4	$50K	Hold	92	–	–	﹤0.01%	1997
2020 Q3	$42K	Hold	92	–	–	﹤0.01%	1947
2020 Q2	$57K	Hold	92	–	–	﹤0.01%	1754
2020 Q1	$44K	Hold	92	–	–	﹤0.01%	1744
2019 Q4	$53K	Hold	92	–	–	﹤0.01%	1886
2019 Q3	$61K	Buy	92 +15	+19%	+$12.5K	﹤0.01%	1767
2019 Q2	$59K	Hold	77	–	–	﹤0.01%	1833
2019 Q1	$54K	Hold	77	–	–	﹤0.01%	1854
2018 Q4	$36K	Hold	77	–	–	﹤0.01%	2000
2018 Q3	$66K	Buy	77 +12	+18%	+$8.66K	﹤0.01%	1829
2018 Q2	$45K	Hold	65	–	–	﹤0.01%	2060
2018 Q1	$29K	Hold	65	–	–	﹤0.01%	2234
2017 Q4	$29K	Hold	65	–	–	﹤0.01%	2248
2017 Q3	$33K	Hold	65	–	–	﹤0.01%	2135
2017 Q2	$36K	Buy	65 +16	+33%	+$10.2K	﹤0.01%	2113
2017 Q1	$33K	Buy	+49	New	+$26.2K	﹤0.01%	2114

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Ameritas Investment Partners's TVRD Position: Q1 2026 in Review

Ameritas Investment Partners held its Tvardi Therapeutics (TVRD) position steady in Q1 2026 at 349 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #3086.

Ameritas Investment Partners first reported a position in TVRD in Q1 2017 and has held it in 33 quarters since. The position peaked at $72K in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

Ameritas Investment Partners held 349 shares of Tvardi Therapeutics worth $1.11K as of Q1 2026.
Ameritas Investment Partners left its Tvardi Therapeutics share count unchanged in Q1 2026.
Tvardi Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #3086 holding.
Ameritas Investment Partners first reported a position in Tvardi Therapeutics in Q1 2017 and has held it in 33 quarters since.
Ameritas Investment Partners's Tvardi Therapeutics position peaked at $72K in Q1 2021.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.